Wyeth Pharmaceuticals / Progenics Pharmaceuticals, Inc.
2005 · Co-Development · $416M · Terminated
Announcement Sentiment
90
Strongly positive
Wyeth and Progenics enter License and Co-Development Agreement for methylnaltrexone (later Relistor) - opioid-induced constipation. Strategically notable; deal value undisclosed in source.